{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,9]],"date-time":"2026-11-09T23:05:01Z","timestamp":1794265501471,"version":"4.9.0"},"reference-count":44,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,8,4]],"date-time":"2022-08-04T00:00:00Z","timestamp":1659571200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,8,4]],"date-time":"2022-08-04T00:00:00Z","timestamp":1659571200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Women's Health"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Cervical cancer is a preventable disease. This study aimed to share the results of the national cervical cancer screening program performed in primary health care institutions in Samsun between 2015 and 2019.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Women aged 30\u201365 years who were screened for cervical cancer in screening centers of Samsun between January 01, 2015, and December 31, 2019, were included in this descriptive study. The data were obtained from the automation program of the \u201cNational Human Papilloma Virus (HPV) Laboratory Application\u201d used by the Provincial Directorate of Health Cancer Unit through filtering the completion time of the tests, and all results were evaluated without sampling. Thus, data were presented using descriptive statistics.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>The mean age of 89,302 women included in the cervical cancer screening program was 45.9\u2009\u00b1\u20099.0 years. Of the samples obtained from the participants, 1.0% were determined as insufficient material, 94.1% as HPV-negative, and 4.9% as HPV-positive. The most common HPV genotypes were 16, 51, 31, and 52. Of the 4337 HPV-positive women, 74.7% of the pap smear results were negative (including infection, 36.5%), and the most common premalignant lesions were atypical squamous cells of undetermined significance in 7.1% and low-grade squamous intraepithelial lesions in 6.9%. HPV 16\/18 was also observed in 31.7% of HPV-positive women. Seven hundred ninety-five women were referred to a specialist physician for further examination and treatment within the scope of the screening algorithm.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Detecting HPV-positivity by reaching more women within the national cervical cancer screening program\u2019s scope is vital in fighting against this disease. The effectiveness of cancer screening programs should be increased by ensuring community participation through awareness activities.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12905-022-01916-6","type":"journal-article","created":{"date-parts":[[2022,8,4]],"date-time":"2022-08-04T13:02:47Z","timestamp":1659618167000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["Results from a cervical cancer screening program in Samsun, Turkey"],"prefix":"10.1186","volume":"22","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3237-7123","authenticated-orcid":false,"given":"Hatice Nilden","family":"Arslan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muhammet Ali","family":"Oruc","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,8,4]]},"reference":[{"issue":"2","key":"1916_CR1","doi-asserted-by":"publisher","first-page":"e191-e203","DOI":"10.1016\/S2214-109X(19)30482-6","volume":"8","author":"M Arbyn","year":"2020","unstructured":"Arbyn M, Weiderpass E, Bruni L, et al. Estimates of incidence and mortality of cervical cancer in 2018: a worldwide analysis. Lancet Glob Health. 2020;8(2):e191-e203. https:\/\/doi.org\/10.1016\/S2214-109X(19)30482-6","journal-title":"Lancet Glob Health"},{"key":"1916_CR2","unstructured":"Republic of Turkey Ministry of Health. https:\/\/hsgm.saglik.gov.tr\/tr\/kanser-istatistikleri\/yillar\/2016-yili-turkiye-kanser-i-statistikleri.html [accessed 11 November 2020]."},{"issue":"5","key":"1916_CR3","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1016\/j.currproblcancer.2018.06.013","volume":"42","author":"AE Rizzo","year":"2018","unstructured":"Rizzo AE, Feldman S. Update on primary HPV screening for cervical cancer prevention. Curr Probl Cancer. 2018;42(5):507\u2013520. https:\/\/doi.org\/10.1016\/j.currproblcancer.2018.06.013","journal-title":"Curr Probl Cancer"},{"key":"1916_CR4","unstructured":"International Agency for Research on Cancer Monographs on the Evaluation of Carcinogenic Risks to Humans. Human papillomaviruses. 2007; Vol.\u00a090. Lyon, France: WHO Press."},{"key":"1916_CR5","unstructured":"World Health Organization. Launch of the Global Strategy to Accelerate the Elimination of Cervical Cancer https:\/\/www.who.int\/news-room\/events\/detail\/2020\/11\/17\/default-calendar\/launch-of-the-global-strategy-to-accelerate-the-elimination-of-cervical-cancer [accessed 28 December 2020]."},{"key":"1916_CR6","unstructured":"World Health Organization. Cervical Cancer Elimination Initiative https:\/\/www.who.int\/initiatives\/cervical-cancer-elimination-initiative [accessed 15 May 2022]."},{"key":"1916_CR7","doi-asserted-by":"publisher","first-page":"952","DOI":"10.3332\/ecancer.2019.952","volume":"13","author":"M Ngoma","year":"2019","unstructured":"Ngoma M, Autier P. Cancer prevention: cervical cancer. Ecancermedicalscience. 2019;13:952. Published 2019 Jul 25. https:\/\/doi.org\/10.3332\/ecancer.2019.952","journal-title":"Ecancermedicalscience"},{"key":"1916_CR8","first-page":"1","volume-title":"WHO guidelines for screening and treatment of precancerous lesions for cervical cancer prevention","author":"M Arbyn","year":"2013","unstructured":"WHO, Arbyn M, Blumenthal P, Cain J, et al. In: Broutet N, et al., editors. WHO guidelines for screening and treatment of precancerous lesions for cervical cancer prevention. WHO. Geneva: World Health Organization; 2013. p. 1\u201340."},{"issue":"9","key":"1916_CR9","doi-asserted-by":"publisher","first-page":"1952","DOI":"10.1002\/ijc.31212","volume":"142","author":"M Gultekin","year":"2018","unstructured":"Gultekin M, Zayifoglu Karaca M, Kucukyildiz I, et al. Initial results of population based cervical cancer screening program using HPV testing in one million Turkish women. Int J Cancer. 2018;142(9):1952\u20131958. https:\/\/doi.org\/10.1002\/ijc.31212","journal-title":"Int J Cancer"},{"key":"1916_CR10","unstructured":"Republic of Turkey Ministry of Health. https:\/\/hsgm.saglik.gov.tr\/tr\/kanser-turleri\/kanser-turleri\/kanser-dairesi-baskanligi-kanser-turleri-serviks-kanseri.html [accessed 11 November 2020]."},{"key":"1916_CR11","unstructured":"Republic of Turkey Ministry of Health. https:\/\/hsgm.saglik.gov.tr\/depo\/birimler\/kanser-db\/yayinlar\/sunular\/Ca_Farkindalik_Egitimi_31.10.2019\/Turkiyede_Birinici_Basamakta_Servikal_Kanser_Taramalari_Doc.Dr.Nejat_Ozgul.pdf [accessed 11 November 2020]."},{"key":"1916_CR12","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1016\/j.pvr.2019.03.002","volume":"7","author":"M Gultekin","year":"2019","unstructured":"Gultekin M, Karaca MZ, Kucukyildiz I, Dundar S, Keskinkilic B, Turkyilmaz M. Mega Hpv laboratories for cervical cancer control: Challenges and recommendations from a case study of Turkey. Papillomavirus Res. 2019;7:118\u2013122. doi:https:\/\/doi.org\/10.1016\/j.pvr.2019.03.002","journal-title":"Papillomavirus Res"},{"key":"1916_CR13","unstructured":"World Health Organization. Fact sheets. Cervical cancer. https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/cervical-cancer. [accessed 15 May 2022]."},{"issue":"4","key":"1916_CR14","doi-asserted-by":"publisher","first-page":"510","DOI":"10.1038\/s41416-020-0920-9","volume":"123","author":"M Kyrgiou","year":"2020","unstructured":"Kyrgiou M, Arbyn M, Bergeron C, et al. Cervical screening: ESGO-EFC position paper of the European Society of Gynaecologic Oncology (ESGO) and the European Federation of Colposcopy (EFC). Br J Cancer. 2020;123(4):510\u2013517. doi:https:\/\/doi.org\/10.1038\/s41416-020-0920-9","journal-title":"Br J Cancer"},{"key":"1916_CR15","doi-asserted-by":"publisher","first-page":"203","DOI":"10.2147\/CLEP.S243546","volume":"12","author":"LT Thomsen","year":"2020","unstructured":"Thomsen LT, Kj\u00e6r SK, Munk C, Frederiksen K, \u00d8rnskov D, Waldstr\u00f8m M. Clinical performance of human papillomavirus (HPV) testing versus cytology for cervical cancer screening: results of a large danish implementation study. Clin Epidemiol. 2020;12:203\u201313. https:\/\/doi.org\/10.2147\/CLEP.S243546 Published 2020 Feb 21.","journal-title":"Clin Epidemiol"},{"issue":"4","key":"1916_CR16","doi-asserted-by":"publisher","first-page":"426","DOI":"10.1136\/ijgc-2020-001285","volume":"30","author":"M Gultekin","year":"2020","unstructured":"Gultekin M, Ramirez PT, Broutet N, Hutubessy R. World Health Organization call for action to eliminate cervical cancer globally. Int J Gynecol Cancer. 2020;30(4):426\u201327. doi:https:\/\/doi.org\/10.1136\/ijgc-2020-001285","journal-title":"Int J Gynecol Cancer"},{"issue":"9","key":"1916_CR17","doi-asserted-by":"publisher","first-page":"e0239611","DOI":"10.1371\/journal.pone.0239611","volume":"15","author":"S Fogelberg","year":"2020","unstructured":"Fogelberg S, Clements MS, Pedersen K, et al. Cost-effectiveness of cervical cancer screening with primary HPV testing for unvaccinated women in Sweden. PLoS One. 2020;15(9):e0239611. Published 2020 Sep 30. doi:https:\/\/doi.org\/10.1371\/journal.pone.0239611","journal-title":"PLoS One"},{"key":"1916_CR18","doi-asserted-by":"publisher","unstructured":"Huh WK, Ault KA, Chelmow D, Davey DD, Goulart RA, Garcia FAR, et al. Use of primary high-risk human papillomavirus testing for cervical cancer screening: interim clinical guidance. Obstet Gynecol. 2015 Feb;125(2):330 \u2013 37. doi: https:\/\/doi.org\/10.1097\/AOG.0000000000000669. PMID: 25569009.","DOI":"10.1097\/AOG.0000000000000669"},{"issue":"7","key":"1916_CR19","doi-asserted-by":"publisher","first-page":"674","DOI":"10.1001\/jama.2018.10897","volume":"320","author":"SJ Curry","year":"2018","unstructured":"US Preventive Services Task Force, Curry SJ, Krist AH, et al. Screening for cervical cancer: US preventive services task force recommendation statement. JAMA. 2018;320(7):674\u201386. https:\/\/doi.org\/10.1001\/jama.2018.10897.","journal-title":"JAMA"},{"issue":"3","key":"1916_CR20","doi-asserted-by":"publisher","first-page":"113","DOI":"10.5694\/mja2.50223","volume":"211","author":"DA Machalek","year":"2019","unstructured":"Machalek DA, Roberts JM, Garland SM, et al. Routine cervical screening by primary HPV testing: early findings in the renewed National Cervical Screening Program. Med J Aust. 2019;211(3):113\u2013119. doi:https:\/\/doi.org\/10.5694\/mja2.50223","journal-title":"Med J Aust"},{"key":"1916_CR21","unstructured":"Bruni L, Albero G, Serrano B, Mena M, G\u00f3mez D, Mu\u00f1oz J, et al. ICO\/IARC Information Centre on HPV and Cancer (HPV Information Centre). Human Papillomavirus and Related Diseases in Asia. Summary Report 17 June 2019. [accessed 28 December 2020]"},{"issue":"5","key":"1916_CR22","doi-asserted-by":"publisher","first-page":"1175","DOI":"10.22034\/APJCP.2018.19.5.1175","volume":"19","author":"G Aimagambetova","year":"2018","unstructured":"Aimagambetova G, Azizan A. Epidemiology of HPV Infection and HPV-Related Cancers in Kazakhstan: a Review. Asian Pac J Cancer Prev. 2018;19(5):1175\u201380. Published 2018 May 26. doi:https:\/\/doi.org\/10.22034\/APJCP.2018.19.5.1175","journal-title":"Asian Pac J Cancer Prev"},{"issue":"6","key":"1916_CR23","doi-asserted-by":"publisher","first-page":"783","DOI":"10.1016\/j.jiph.2017.01.011","volume":"10","author":"TY Zhong","year":"2017","unstructured":"Zhong TY, Zhou JC, Hu R, Fan XN, Xie XY, Liu ZX, et al. Prevalence of human papillomavirus infection among 71,435 women in Jiangxi Province, China. J Infect Public Health. 2017 Nov-Dec;10(6):783\u201388. doi: 10.1016\/j.jiph.2017.01.011. Epub 2017 Feb 15. PMID: 28214188.","journal-title":"J Infect Public Health"},{"key":"1916_CR24","doi-asserted-by":"publisher","unstructured":"Hooi DJ, Lissenberg-Witte BI, Kenter G, de Koning MNC, Gomes Bravio I, Ardts K, et al. Human papillomavirus (HPV) prevalence and associated risk factors in women from Cura\u00e7ao. PLoS One. 2018 Jul 13;13(7):e0199624. doi: https:\/\/doi.org\/10.1371\/journal.pone.0199624. PMID: 30005066; PMCID: PMC6044524.","DOI":"10.1371\/journal.pone.0199624"},{"key":"1916_CR25","first-page":"36","volume":"25","author":"M Ceyhan","year":"2012","unstructured":"Ceyhan M. Human papillomavirus (HPV) a\u015f\u0131lar\u0131. Klinik Geli\u015fim Dergisi 2012;25:36\u20139. http:\/\/www.klinikgelisim.org.tr\/kg_25_1\/kg_25_1.pdf","journal-title":"Klinik Geli\u015fim Dergisi"},{"key":"1916_CR26","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1111\/tog.12279","volume":"18","author":"M Aref-Adib","year":"2016","unstructured":"Aref-Adib M, Freeman-Wang T. Cervical cancer prevention and screening: the role of human papillomavirus testing. The Obstet Gynaecol 2016;18:251\u201363. https:\/\/doi.org\/10.1111\/tog.12279","journal-title":"The Obstet Gynaecol"},{"key":"1916_CR27","doi-asserted-by":"publisher","unstructured":"At\u0131gan A, Erayd\u0131n E. Prevalence of Human Papillomavirus (HPV) Types. KS\u00dc T\u0131p Fak Der. 2020; 15(2): 35\u201340. https:\/\/doi.org\/10.17517\/ksutfd.607179","DOI":"10.17517\/ksutfd.607179"},{"issue":"1","key":"1916_CR28","doi-asserted-by":"publisher","first-page":"33","DOI":"10.5505\/TurkHijyen.2019.68984","volume":"77","author":"\u00d6 Aydemir","year":"2020","unstructured":"Aydemir \u00d6, Terzi HA, K\u00f6ro\u011flu M, Turan G, Alt\u0131ndi\u015f M, Karake\u00e7e E. Human papillomavirus positivity and genotype distribution in cervical samples. Turk Hij Den Biyol Derg, 2020; 77(1): 33\u201340. DOI ID: 10.5505\/TurkHijyen.2019.68984","journal-title":"Turk Hij Den Biyol Derg"},{"issue":"2","key":"1916_CR29","doi-asserted-by":"publisher","first-page":"35","DOI":"10.5835\/jecm.omu.36.02.001","volume":"36","author":"M Alan","year":"2019","unstructured":"Alan M, Oruc MA, Kurt M, Alan Y, Sanci M. Evaluation of colposcopy results for patients who are HPV DNA positive in KETEM. J Exp Clini Med. 2019; 36(2): 35\u201342.doi: https:\/\/doi.org\/10.5835\/jecm.omu.36.02.001","journal-title":"J Exp Clini Med"},{"issue":"4","key":"1916_CR30","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1158\/1055-9965.EPI-12-1406","volume":"22","author":"M Schiffman","year":"2013","unstructured":"Schiffman M, Wentzensen N. Human papillomavirus infection and the multistage carcinogenesis of cervical cancer. Cancer Epidemiol Biomarkers Prev. 2013;22(4):553\u2013560. doi:https:\/\/doi.org\/10.1158\/1055-9965.EPI-12-1406","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"1916_CR31","doi-asserted-by":"publisher","unstructured":"Arbyn M, Ronco G, Anttila A, et al. Evidence regarding human papillomavirus testing in secondary prevention of cervical cancer [published correction appears in Vaccine. 2013 Dec 16;31(52):6266]. Vaccine. 2012;30 Suppl 5:F88-F99. doi:https:\/\/doi.org\/10.1016\/j.vaccine.2012.06.095","DOI":"10.1016\/j.vaccine.2012.06.095"},{"key":"1916_CR32","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1186\/s12916-019-1460-0","volume":"17","author":"CA Aitken","year":"2019","unstructured":"Aitken CA, van Agt H, Siebers AG, van Kemenade F, Niesters HGM, Melchers WJG, et al. Introduction of primary screening using high-risk HPV DNA detection in the Dutch cervical cancer screening programme: a population\u2010based cohort study. BMC Med 2019; 17: 228. https:\/\/doi.org\/10.1186\/s12916-019-1460-0","journal-title":"BMC Med"},{"key":"1916_CR33","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1186\/s13027-020-00280-0","volume":"15","author":"A Ernstson","year":"2020","unstructured":"Ernstson A, Urdell A, Forslund O, Borgfeldt C. Cervical cancer prevention among long-term screening non-attendees by vaginal self-collected samples for hr-HPV mRNA detection. Infect Agent Cancer. 2020;15:10. Published 2020 Feb 13. doi:https:\/\/doi.org\/10.1186\/s13027-020-00280-0","journal-title":"Infect Agent Cancer"},{"key":"1916_CR34","doi-asserted-by":"publisher","unstructured":"Virtanen A, Anttila A, Nieminen P. The costs of offering HPV-testing on self-taken samples to non-attendees of cervical screening in Finland. BMC Womens Health. 2015;15:99. Published 2015 Nov 5. doi:https:\/\/doi.org\/10.1186\/s12905-015-0261-7","DOI":"10.1186\/s12905-015-0261-7"},{"issue":"17","key":"1916_CR35","doi-asserted-by":"publisher","first-page":"6245","DOI":"10.3390\/ijerph17176245","volume":"17","author":"EL Wong","year":"2020","unstructured":"Wong EL, Cheung AW, Wong AY, Chan PK. Acceptability and feasibility of HPV self-sampling as an alternative primary cervical cancer screening in under-screened population groups: a cross-sectional study. Int J Environ Res Public Health. 2020;17(17):6245. https:\/\/doi.org\/10.3390\/ijerph17176245 Published 2020 Aug 27.","journal-title":"Int J Environ Res Public Health"},{"key":"1916_CR36","doi-asserted-by":"publisher","first-page":"k4823","DOI":"10.1136\/bmj.k4823","volume":"363","author":"M Arbyn","year":"2018","unstructured":"Arbyn M, Smith SB, Temin S, Sultana F, Castle P; Collaboration on Self-Sampling and HPV Testing. Detecting cervical precancer and reaching underscreened women by using HPV testing on self samples: updated meta-analyses. BMJ. 2018;363:k4823. Published 2018 Dec 5. doi:https:\/\/doi.org\/10.1136\/bmj.k4823","journal-title":"BMJ"},{"issue":"3","key":"1916_CR37","doi-asserted-by":"publisher","first-page":"357","DOI":"10.33631\/duzcesbed.749205","volume":"10","author":"G Uluda\u011f","year":"2020","unstructured":"Uluda\u011f G, Gams\u0131zkan Z, Sungur M. Evaluation of Women\u2019s health beliefs about cervical cancer and screening. D\u00dc Sagl\u0131k Bil Enst Derg. 2020;10(3):357\u201362. https:\/\/doi.org\/10.33631\/duzcesbed.749205.","journal-title":"D\u00dc Sagl\u0131k Bil Enst Derg"},{"key":"1916_CR38","doi-asserted-by":"publisher","unstructured":"Ozturk Y. Obstacles preventing women from having pap smear screening test. S\u00fcrekli T\u0131p E\u011fitimi Dergisi 2020, 29: 61 \u2013 8. https:\/\/doi.org\/10.17942\/sted.466811","DOI":"10.17942\/sted.466811"},{"key":"1916_CR39","doi-asserted-by":"publisher","unstructured":"K\u00fc\u00e7\u00fckceran H, A\u011faday\u0131 E, \u015eent\u00fcrk H. Evaluation of the approaches of women registered to a family medicine unit in Ankara regarding having cervical cancer screening tests TJFMPC, 2020;14 (2): 259\u201366. https:\/\/doi.org\/10.21763\/tjfmpc.650940","DOI":"10.21763\/tjfmpc.650940"},{"issue":"6","key":"1916_CR40","doi-asserted-by":"publisher","first-page":"528","DOI":"10.1177\/1010539516654541","volume":"28","author":"K S\u00f6zmen","year":"2016","unstructured":"S\u00f6zmen K, Unal B, Sakarya S, et al. Determinants of breast and cervical cancer screening uptake among women in Turkey. Asia Pacific Journal of Public Health. 2016;28(6):528\u201338. https:\/\/doi.org\/10.1177\/1010539516654541.","journal-title":"Asia Pacific Journal of Public Health"},{"issue":"4","key":"1916_CR41","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1258\/jms.2009.009073","volume":"16","author":"J Waller","year":"2009","unstructured":"Waller J, Bartoszek M, Marlow L, Wardle J. Barriers to cervical cancer screening attendance in England: a population-based survey. Journal of medical screening, 2009;16(4), 199\u2013204. https:\/\/doi.org\/10.1258\/jms.2009.009073","journal-title":"Journal of medical screening"},{"issue":"5","key":"1916_CR42","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1046\/j.1525-1438.2002.01170.x","volume":"12","author":"MM Watkins","year":"2002","unstructured":"Watkins MM, Gabali C, Winkleby M, Gaona E, Lebaron S. Barriers to cervical cancer screening in rural Mexico. Int J Gynecol Cancer. 2002;12(5):475\u2013479. doi:https:\/\/doi.org\/10.1046\/j.1525-1438.2002.01170.x","journal-title":"Int J Gynecol Cancer"},{"issue":"4","key":"1916_CR43","doi-asserted-by":"publisher","first-page":"e57","DOI":"10.3802\/jgo.2018.29.e57","volume":"29","author":"N Thapa","year":"2018","unstructured":"Thapa N, Maharjan M, Petrini MA, et al. Knowledge, attitude, practice and barriers of cervical cancer screening among women living in mid-western rural, Nepal. J Gynecol Oncol. 2018;29(4):e57. doi:https:\/\/doi.org\/10.3802\/jgo.2018.29.e57","journal-title":"Nepal. J Gynecol Oncol"},{"key":"1916_CR44","doi-asserted-by":"publisher","unstructured":"Hamdiui N, Marchena E, Stein ML, et al. Decision-making, barriers, and facilitators regarding cervical cancer screening participation among Turkish and Moroccan women in the Netherlands: a focus group study [published online ahead of print, 2021 Jan 7]. Ethn Health. 2021;1\u201319. doi:https:\/\/doi.org\/10.1080\/13557858.2020.1863921","DOI":"10.1080\/13557858.2020.1863921"}],"container-title":["BMC Women's Health"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12905-022-01916-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12905-022-01916-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12905-022-01916-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,8,4]],"date-time":"2022-08-04T13:03:17Z","timestamp":1659618197000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcwomenshealth.biomedcentral.com\/articles\/10.1186\/s12905-022-01916-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8,4]]},"references-count":44,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["1916"],"URL":"https:\/\/doi.org\/10.1186\/s12905-022-01916-6","relation":{},"ISSN":["1472-6874"],"issn-type":[{"value":"1472-6874","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,8,4]]},"assertion":[{"value":"2 March 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 August 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 August 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was conducted in accordance with the Declaration of Helsinki 1975, revised in Hong Kong 1989.  All the study procedures were approved by the Clinical Research Ethics Committee (OMUKAEK 2020\/79) of Ondokuz Mayis University.  Written informed consent was obtained from all participants in the screening program.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"331"}}